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Abstract
Background:  Poly(ADP-ribosylation) is a post-translational modification of nuclear proteins
involved in several cellular events as well as in processes that characterize the infective cycle of
some viruses. In the present study, we investigated the role of poly(ADP-ribosylation) on Epstein-
Barr Virus (EBV) lytic cycle activation.
Results: Inhibition of PARP-1 by 3-aminobenzamide (3-ABA) during EBV induction, diminished cell
damage and apoptosis in the non-productive Raji cell line while markedly reducing the release of
viral particles in the productive Jijoye cells. Furthermore, incubation with 3-ABA up-regulated the
levels of LMP1 and EBNA2 latent viral proteins. At the same time, it slightly affected the expression
of the immediate early BZLF1 gene, but largely down-regulated the levels of the early BFRF1
protein. The modulation of the expression of both latent and lytic EBV genes appeared to be post-
transcriptionally regulated.
Conclusion: Taken together the data indicate that PARP-1 plays a role in the progression of EBV
lytic cycle and therefore, PARP inhibitors might represent suitable pharmacological adjuncts to
control viral spread in EBV productive infection.
Background
Epstein Barr Virus (EBV), the ethiological agent of infec-
tious mononucleosis (IM) is associated with a number of
tumors such as Burkitt's lymphoma (BL), Hodgkin's dis-
ease (HD), nasopharingeal carcinoma (NPC) and with
lymphoproliferative diseases in the immunocompro-
mised individuals [1]. The virus has two distinct cycles of
infection: latent and lytic. During latency, a limited
number of genes is differentially expressed. These include
six nuclear antigens, designated as EBNA-1 to -6, three
membrane proteins, indicated as LMP-1, -2A, and -2B and
two small non-polyadenylated RNAs (EBERs).
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EBV nuclear antigen EBNA1 is required for latent replica-
tion, episomal mainteinance and viral genome segrega-
tion [2]. EBNA2, EBNA-3A, -3B and -3C are
transcriptional activators of viral and cellular genes. With
the exception of EBNA-3B, they all concurr with the EBERs
to B cell transformation [3].
Among the latent genes, LMP-1 is essential for B-lym-
phocyte transformation. It upregulates anti-apoptotic
genes such as Bcl-2 and Mcl-1 [4], induces several cell sur-
face adhesion molecules and activation markers and stim-
ulates cytokine production [5].
During the lytic cycle, the sequential expression of imme-
diate early, early and late genes, leads to production of
viral particles. The EBV lytic cycle cascade initiates with
the expression of two immediate-early genes: BZLF1
encoding for ZEBRA, and BRLF1 encoding for Rta. The
two viral products promote each other expression, trans-
activate separate classes of EBV lytic genes and together
coordinate the activation of a third class of lytic genes [1].
In vivo, reactivation of the virus occurs in terminally dif-
ferentiated plasma cells in response to antigen stimula-
tion [6]. In vitro, the lytic cycle can be induced by different
agents, such as phorbol esters, sodium butyrate, antiim-
munoglobulins (anti-IgG) and calcium ionophores [7-9].
Although many studies have been devoted to elucidate
the molecular events underlying EBV activation, the role
that epigenetic modifications play in this process, is still
unclear. In this respect, histone acetylation as well as DNA
methylation of the BZLF1 promoter (Zp) have been
shown to occur in the transition from the latent to lytic
phase [10].
Poly(ADP-ribosylation) is a post-translational modifica-
tion of nuclear proteins that appears to be involved in sev-
eral cellular events such as DNA repair, cell
differentiation, apoptosis and tumor promotion [11].
The poly(ADP-ribose)polymerase (PARP-1), a zinc-bind-
ing nuclear enzyme, catalyzes the covalent addition of the
ADP-ribose moiety of nicotinamide adenine dinucleotide
(NAD+) to nuclear proteins including histones, transcrip-
tion factors and PARP itself as well as the subsequent elon-
gation step of the polymer. Because of its negative charges,
the poly(ADP-ribose)polymer highly affects the function
of target proteins [12]. Moreover, also non-covalently
bound poly(ADP-ribose)polymers have been shown to
modulate the activity of several proteins [13].
PARP-1 is required during transcriptional activation of
Drosophila puff loci [14], it is a structural component of
chromatin in polytene chromosome [15] and modulates
the activity of transcription factors [16].
It has been shown that poly(ADP-ribosylation) is needed
for fundamental events that characterize the infective
cycle of several viruses. In fact this process is involved in
the regulation of the replication and transcription activa-
tor (RTA) of gamma-2 herpesvirus [17], in the replication
and integration of HIV-1 [18,19], while it contributes to
decapsidation of adenovirus [20] and papillomavirus
[21]. In addition, recent data indicate that macro domains
of some RNA viruses bind efficiently free and automodi-
fied PARP-1, possibly modulating the host response to
viral infection [22].
In this study we have examined the role that poly(ADP-
ribosylation) plays in the EBV activation process by induc-
ing the lytic cycle in the presence of 3-aminobenzamide
(3-ABA), a well known inhibitor of PARP-1 activity [23].
To this end we have treated Burkitt lymphoma-derived
Raji and Jijoye cells with agents able to induce EBV lytic
cycle. However, a deletion of EBV genome in Raji cells pre-
vents late gene expression, leading to an abortive cycle
[24], while the complete productive infection is sup-
ported by Jijoye cells.
It has been shown that 3-ABA might also inhibit cell death
and apoptosis [25], possibly by interfering with cytoskel-
eton organization [26] and/or cell-cycle checkpoint mech-
anisms [27].
We report here that treatment of Burkitt's lymphoma cells
with 3-ABA, besides exerting cytoprotective and antiapop-
totic effects, modulates the expression of both latent and
lytic EBV genes impairing viral lytic cycle progression and
particles release.
Results
Effect of 3-ABA on EBV lytic cycle activation and apoptosis
As previously reported, exposure of Raji cells to P(BU)2,
sodium butyrate and TGF-β2, induces EBV lytic cycle in
about 70% of the population, as judged by immunofluo-
rescence detection of EA expression [28].
The effect of PARP inhibition on EBV early antigen expres-
sion was therefore evaluated on Raji cells induced in the
presence or in the absence of 3-ABA and on latently-
infected Raji cells used as controls. Fig. 1 shows represent-
ative microphotographs obtained from cells collected at
different times during incubation. The image in a) shows
control cells, negative for EA staining, independently of
the incubation with the PARP-1 inhibitor. The pictures
reported in column b) show that after 24 hours incuba-
tion with lytic cycle inducers, FITC-labeled antibodiesInfectious Agents and Cancer 2007, 2:18 http://www.infectagentscancer.com/content/2/1/18
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detected EA in a large percentage of the cell population,
and the intensity of the fluorescence increased at 48
hours. In comparison, the expression of EA in the pres-
ence of 3-ABA (panel c) occurred in a lower number of
cells at 24 hours while at 48 hours the percentage of pos-
itive cells and the intensity of the signal seemed compara-
ble or even higher than what reported in panel b).
At 72 hours, in the absence of 3-ABA, along with posi-
tively stained cells, a number of damaged cells, smaller
than intact ones, could be visualized. In contrast, Raji cells
incubated with PARP-1 inhibitor were stained similarly to
the samples incubated for 48 hours, with the signal
mainly localized at the periphery of the cells.
cytofluorymetric analysis of cells treated as for the IF stud-
ies, indicated that the percentage of the cell population
undergoing apoptosis (pre-G1 peak) was slightly affected
by the presence of the PARP-1 inhibitor within the first 48
hours of incubation. However, at 72 hours, a 34% of
apoptotic cells was observed in induced Raji cells, while
only a 20% was measured when lytic cycle activation was
carried out in the presence of 3-ABA (data not shown).
To further investigate the protective effect of 3-ABA during
EBV lytic cycle activation the rate of apoptosis was tested
by Annexin V assay. Fig. 2 shows the PI versus Annexin V
dot plot of a representative experiment performed on Raji
cells treated as above described. The data of the cytofluo-
rymetric analysis indicate that after 48 and 72 hours of
exposure to the lytic cycle inducing compounds, cell via-
bility was reduced to about 87 and 74%, respectively,
while the corresponding measurements of the cells
exposed to 3-ABA were 97 and 89%. At the same time
points, the percentages of Annexin V-positive cells were
11 and 23%, respectively. However, the fraction of apop-
totic cells was markedly lower (1.3 and 7.2%) in the sam-
ples incubated in the presence of 3-ABA.
Effect of 3-ABA on the early and on late phases of EBV lytic 
cycle
To evaluate the effect of 3-ABA on the early phases of EBV
lytic cycle, the percentage of EA-positive cells was deter-
mined by cytofluorymetric analysis in Raji and Jijoye cells
incubated with lytic cycle activators in the absence or in
the presence of the PARP inhibitor. The results reported in
the upper panel of Fig 3 show that in Raji cells, the per-
centage of the population expressing the EA after 24 and
48 hours of induction was not significantly altered by the
presence of 3-ABA, representing about 20 and 50%,
respectively. In contrast, after 72 hour of incubation with
the inducers, about 20% increment of EA-positive cells
was observed when the PARP inhibitor was added to the
colture.
The lower panel of Fig. 3 illustrates the results obtained
from Jijoye cells. Since in this cell line, EBV supports the
complete lytic cycle, samples were collected up to 24
hours, when most of the cells were intact. The data
reported show that spontaneous lytic cycle activation
occurred in the absence of the inducing compounds in
about 10% of the untreated cells. Eight hours after the
addition of the inducers, about 25% of Jijoye cells became
positive for the EA; this fraction was slightly lower when
the cells were induced in the presence of the PARP inhib-
itor. In contrast, after 24 hours, more than 20% of the cells
incubated with 3-ABA were still expressing the EA, while
Representative microphotographs showing early antigen  expression in Raji cells induced with or without 3-ABA Figure 1
Representative microphotographs showing early 
antigen expression in Raji cells induced with or with-
out 3-ABA. EBV lytic cycle was induced as described in the 
Methods in the absence (b), or in the presence (c) of 3 mM 
3-ABA. Latently infected Raji cells exposed or not to 3-ABA 
(a) were used as control. At the indicated times (24, 48 and 
72 hours) cells were collected and stained with FITC-labeled 
EA antibodies and Blue Evans dye.Infectious Agents and Cancer 2007, 2:18 http://www.infectagentscancer.com/content/2/1/18
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this fraction was reduced to 5% in the absence of the
inhibitor.
In order to assess whether the higher percentage of EA-
positive cells in the samples treated with 3-ABA for 24
hours reflected an impairment in EBV lytic cycle comple-
tion, the release of viral DNA in the colture medium, was
determined.
Fig. 4 shows the results of the hybridization of BamH1-
digested EBV DNA obtained from the supernatant of cells
induced for different lengths of time in the presence or in
the absence of 3-ABA, with a probe for the BamH1 Z
region of the EBV genome. Quantification of the signal
corresponding to the 1700 bp specific fragment revealed
that at 48 hours, in the presence of the PARP inhibitor,
viral DNA released in the supernatant was about half the
amount detected in the absence of 3-ABA.
Effect of PARP-1 inhibitor on EBV protein levels
To evaluate the effect of PARP-1 inhibition on EBV gene
expression, the levels of two latent (LMP1 and EBNA-2),
and two lytic (BZLF1 and BFRF1) viral proteins, were ana-
lyzed by Western blot.
Fig. 5 shows LMP1 and EBNA2 expression in induced Raji
cells incubated for different times with or without 3-ABA.
In the upper panel it appears that LMP1 levels strongly
increased during incubation with EBV lytic cycle inducers.
However, the increment was larger in the cells induced in
the presence of the PARP-1 inhibitor. In particular, in the
latter, at 72 hours, the level of the protein was about 1.6
fold higher than that measured in the absence of 3-ABA.
In the lower panel, the results of a representative blot
hybridized with EBNA2 antibodies are shown. Similarly
to what observed for LMP1, EBNA2 levels in the cells
induced for 48 and 72 hours in the presence of 3-ABA
Cytofluorymetric analysis of apoptotic Raji cells Figure 2
Cytofluorymetric analysis of apoptotic Raji cells. Raji cells were induced in the absence or in the presence of 3-ABA as 
for Fig.1. At the indicated times, cells were collected and subjected to Annexin V-FITC/PI staining as reported in the Methods. 
The upper part of the figure shows the dot blots of PI vs. Annexin V stain. All parameters and region settings were kept identi-
cal throughout all measurements. The table illustrates the percentages of necrotic cells (PI); secondary necrotic cells (PI/A); via-
ble cells (V); Annexin V-positive (apoptotic) cells (A).Infectious Agents and Cancer 2007, 2:18 http://www.infectagentscancer.com/content/2/1/18
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appeared about 2.5 fold higher than those measured in
the absence of the inhibitor. Similar results were obtained
by using the structurally unrelated PARP-1 inhibitor PJ 34.
Fig. 6 illustrates the results obtained when the blots were
tested with antibodies for BZLF1 or BFRF1, an immediate
early and an early EBV lytic gene, respectively. It is shown
that BZLF1 expression gradually increased during the first
48 hours that followed the addition of lytic cycle activa-
tors to Raji cells. In the presence of 3-ABA the extent of this
increment was slightly lower than that observed in the
absence of the inhibitor. The middle panel shows that the
signal identifying BFRF1 appeared 48 hours after EBV
induction and increased of about two fold at 72 hours.
Remarkably, the increment of BFRF1 protein in Raji cells
induced in the presence of 3-ABA was about 50% lower
than that measured for both time points in the absence of
the inhibitor.
To verify that equal amounts of cellular proteins had been
loaded on gels, blots were hybridized with actin antibod-
ies. Surprisingly, incubation of Raji cells with EBV lytic
cycle inducers led to a 2 fold increment of actin levels.
This increment was largely prevented when EBV induction
was carried out in the presence of 3-ABA.
Antibodies directed to glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) were used to verify that similar
amounts of proteins had been loaded onto each gel track
(data not shown).
The effect of PARP inhibitor on EBV latent and lytic gene
expression was also evaluated in Jijoye cells treated with
lytic cycle inducing agents. The results obtained with this
cell line were substantially similar to those above
described for Raji cells (data not shown).
Effect of PARP-1 inhibitor on EBV mRNA levels
To assess whether the differences observed in the levels of
EBV latent and lytic products resulted from changes in the
rate of transcription of the corresponding genes, mRNA
levels were measured by RT-PCR. Fig. 7 illustrates the
results obtained with primers for LMP1, EBNA2, BZLF1
Cytoflowrimetric analysis of EA expression in Raji and Jijoye  cells Figure 3
Cytoflowrimetric analysis of EA expression in Raji 
and Jijoye cells. EBV lytic cycle was induced in Raji and 
Jijoye cells in the absence or in the presence of 3-ABA as 
described in the Methods. At the indicated times, cels were 
analyzed by flowcytometry after staining with FITC-EA anti-
bodies. The bargraph represents the percentages of EA-posi-
tive cells determined after induction in the absence (dark 
bars) or in the presence (light bars) of 3-ABA. Error bars are 
the means ± SD of three independent experiments.
Detection of EBV DNA released in the colture medium of  induced Jijoye cells Figure 4
Detection of EBV DNA released in the colture 
medium of induced Jijoye cells. Jijoye cells were induced 
with or without 3-ABA as described in the Methods. Viral 
DNA purified from the colture medium was digested with 
BamH1 and analyzed by Southern blot with a DIG-tailed 
probe specific for the BamH1 Z region of the EBV genome. 
The values in the graph were obtained by densitometric 
measurements of the 1700 bp BamH1 Z fragment of the viral 
DNA collected in the supernatant of Jijoye cells induced in 
the absence (filled circles) or in the presence (open circles) 
of 3-ABA.Infectious Agents and Cancer 2007, 2:18 http://www.infectagentscancer.com/content/2/1/18
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and BFRF1 respectively. It appears that for the two latent
genes, as well as for the two lytic genes, the rates of tran-
scription were not significantly affected by the addition of
3-ABA during EBV induction.
Control experiments performed with the primers for the
GAPDH gene, confirmed that equal amounts of total RNA
had been subjected to RT-PCR (data not shown).
Discussion
The present study investigated the role that poly(ADP-
ribosylation) plays during EBV lytic cycle activation in
Burkitt's lymphoma-derived Raji and Jijoye cells, the first
supporting only the early phases of the lytic cycle, the lat-
ter allowing the complete, productive infection. We report
here that upon induction of EBV lytic cycle in the presence
of 3-ABA, high levels of EA were detected in both cell lines
even at late times of incubation while a reduced amount
of viral DNA was measured in the colture medium of the
productive Jijoye cells. These data strongly suggest that the
PARP inhibitor affects the progression and the comple-
tion of EBV lytic cycle.
Moreover, our observations indicate that incubation with
3-ABA during EBV induction favors the maintenance of
Raji cell integrity and reduces the apoptotic events.
LMP1 and EBNA2 expression by Western blot analysis Figure 5
LMP1 and EBNA2 expression by Western blot analy-
sis. Cell lysates obtained from Raji cells treated and collected 
as reported in Fig.1, were subjected to SDS-PAGE. The blots 
were probed with LMP-1 and EBNA2 antibodies. Specific sig-
nals, quantified by densitometry are expressed as arbitrary 
units in the bargraph. Error bars are the means ± SD of three 
independent experiments. Dark bars: induced Raji cells; light 
bars: induced Raji cells + 3-ABA.
BZLF1 and BFRF1 expression by Western blot analysis Figure 6
BZLF1 and BFRF1 expression by Western blot analy-
sis. Cell lysates obtained from Raji cells treated and collected 
as reported in Fig.1, were subjected to SDS-PAGE. The blots 
were probed with BZLF1, BFRF1 and actin antibodies. Spe-
cific signals, quantified by densitometry are expressed as arbi-
trary units in the bargraph. Error bars are the means ± SD of 
three independent experiments. Dark bars: induced Raji 
cells; light bars: induced Raji cells + 3-ABA.
Expression of EBV latent and lytic genes by RT-PCR Figure 7
Expression of EBV latent and lytic genes by RT-PCR. 
Total RNA was purified from Raji cells induced in the 
absence or in the presence of 3-ABA and collected at the 
indicated times. mRNA levels of LMP-1, EBNA2, BZLF1 and 
BFRF1 were determined by RT-PCR as described in the 
Methods. Amplification products were separated on a 1.5% 
agarose gel and stained with ethidium bromide.Infectious Agents and Cancer 2007, 2:18 http://www.infectagentscancer.com/content/2/1/18
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It has been reported that activators of EBV lytic program
induce apoptosis, but that lytic gene expression protects
from cell death [29]. Nevertheless, in Raji cells where the
lytic cycle is blocked at the early phases, a prolonged incu-
bation with the inducers, resulted in about 20% of apop-
tosis. The large reduction of apoptotic cells detected in the
presence of 3-ABA confirms the cytoprotective effect that
has been reported for the PARP-1 inhibitor in different
experimental model of apoptosis [30,27].
Besides, PARP-1 inhibition alters the expression of two
latent and two lytic viral proteins. The observed up-regu-
lation of the latent LMP1 and EBNA2 and the down-regu-
lation of the lytic BZLF1 and BFRF1 proteins, concur with
impairment of the viral activation process.
Because the up-regulation of LMP1 and EBNA2 expres-
sion seems to take place at the post-transcriptional level it
is reasonable to hypothesize a lower rate of turnover for
the two viral products. Little is known about the degrada-
tion pathway of EBNA 2. However, it has been shown that
the turnover of LMP-1, ubiquitinated in the short cyto-
plasmic N-terminus, occurs via the proteasome [31]. Since
PARP-1 can stimulate proteasome activity by the addition
of ADP polymers to the 20S proteasome subunit [32], the
increment of LMP1 protein, detected in induced Raji cells
exposed to 3-ABA might result from a lower activity of the
proteasomal complex.
In agreement with the stimulatory effect of LMP1 on Bcl2
expression [4], the higher levels of the antiapoptotic pro-
tein detected in 3-ABA treated cells (data not shown)
might also contribute to the cyto-protective effect
observed with PARP-1 inhibitor.
Our data indicate that actin levels rise in the presence of
EBV lytic cycle inducers. This event is possibly related to
actin remodeling by phorbol esthers [33] and/or by LMP1
activation of Rho GTPase [34]. The addition of PARP-1
inhibitor to induced Raji cells, largely prevents actin incre-
ment. Several reports indicate that 3-ABA activity is asso-
ciated with cell type specific cytoscheleton
rearrangements, mostly due to modification of actin
polymerization or assembly [26,35]. Our results lead to
hypotesize that 3-ABA treatment might, in addition, inter-
fere with the mechanisms that regulate actin intracellular
levels.
The present work demonstrates that the increment of the
early EBV protein BFRF1, was dramatically inhibited when
EBV lytic cycle was induced in the presence of 3-ABA while
only a slight decrement was observed for BZLF1 protein.
These observations indicate that PARP-1 inhibition does
not affect the switch from the latent to the lytic cycle of
EBV infection, but rather the following event/s leading to
the sequential expression of EBV lytic genes cascade. In
this respect, PARP-1 inhibition could contribute to deter-
mine an abortive lytic cycle, a phenomenon that might be
relevant in the early phases of B lymphocytes infection.
Because PARP-1 is involved in decondensation of high-
order chromatin structure [12,36], inhibition of the
enzyme might determine a lower accessibility of DNA to
the transcription machinery. Moreover, PARP-1 activity is
required to repair DNA strand break. We do not know
whether the inhibition of this function might impair the
successful transcription of some EBV lytic genes. Our data
however, indicating that the rates of transcription of
BFRF1 are not influenced by the 3-ABA, suggest that the
effect of 3-ABA on BFRF1 protein levels is either indirect
or mainly exerted at the post-transcriptional level.
Conclusion
The data reported in the present study indicate that PARP-
1 inhibition impairs EBV lytic cycle progression, thereby
affecting the release of viral particles.
We envisage that these results might lead to consider
PARP-1 inhibitors as potential therapeutic agents to con-
trol the spread of EBV productive infection.
Methods
Cell culture conditions
Burkitt's lymphoma derived Raji and Jijoye cells were
grown in RPMI 1640 medium (Sigma) supplemented
with 1% penicillin-streptomycin and 5% fetal calf serum
(FCS) in a 5% CO2 atmosphere.
Induction of EBV lytic cycle and treatment with 3-ABA
EBV lytic cycle was induced in Raji cells as previously
described [28] in the presence or in the absence of 3 mM
3-ABA. Control experiments were carried out with
latently-infected cells, incubated with 3 mM 3-ABA. At 0,
24, 48 and 72 hours, cell samples were collected and ana-
lysed as described below. Cell viability was assessed by
trypan blue exclusion.
Fluorescence microscopy
Treated cells were smeared on slide, fixed and permeabi-
lized with methanol:acetone (2:1) at -20°C and then
rehydrated with phosphate buffered saline solution
(PBS), pH 7.4. Fixed cells were incubated with FITC-con-
jugated F6-Ester 2 antibodies [37] recognizing EBV early
antigens (EA) diluted 1:40 in PBS/1% BSA, for 1 hour at
37°C. After three washes with PBS, cells were stained with
100 μg/ml Blue Evans dye for 5 min at room temperature.
After three more washes, slides were mounted with 50%
glycerol in PBS and analyzed with a Leitz Orthoplan
immunofluorescence microscope. Images were recorded
by an Olympus digital camera.Infectious Agents and Cancer 2007, 2:18 http://www.infectagentscancer.com/content/2/1/18
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Cytofluorymetric determinations
Cells incubated with EBV lytic cycle inducers in the
absence or in the presence of 3-ABA were collected at dif-
ferent times. The distribution of Raji cells in the cell cycle
phases was determined by FACS analysis after DNA stain-
ing with propidium iodide (PI). Cell samples were
washed with PBS and centrifuged for 5 min at 400 x g. The
cell pellet was incubated for 1 h at 4°C in 70% ethanol,
washed again with PBS, and finally stained in the dark for
1 hour with 100 μg/ml of PI and 100 μg/ml RNase in PBS.
pre-G1 peak, characterized by the lowest PI staining inten-
sity, mainly represented apoptotic cells.
To evaluate apoptosis with an additional method, cells
treated and collected as above described were resus-
pended in ice-cold binding buffer and stained by Annexin
V-FITC Kit (Beckman Coulter) according to the accompa-
nying procedure.
To measure EA expression, cells incubated with EBV lytic
cycle inducers in the absence or in the presence of 3-ABA
were collected at different times, washed with PBS and
fixed in ice cold PBS containing 2% paraformaldehyde for
20 min. After two more washes in PBS, the cells were
resuspended in 60 μM digitonin containing FITC-conju-
gated F6-Ester 2 antibodies diluted 1:20 and incubated for
60 min at 37°C.
All cytofluorymetric determinations were carried out by
Coulter EPICS XL.
Detection of EBV genome released in the supernatant
Jijoye cells (1.5 x 106) were exposed to lytic cycle inducing
agents with or without 3-ABA, for 12, 24 and 48 hours.
Colture supernatants were concentrated in Vivaspin 2,
10000 MWCO HY (Sartorius) by a centrifugation in swing
rotor for 5 min at 4000 x g. Viral DNA was purified from
the concentrated samples by QIAamp DNA Mini kit
according to the manufacturer instruction and subjected
to BamH1 digestion. DNA (10 μl) was resolved by electro-
phoresis on a 0.7% agarose gel and blotted on Nylon
membrane (Roche Diagnostic). Hybridization was carried
out in DIG Easy granules solution (Roche Diagnostic)
with 50 ng/ml of a Digoxigenin-tailed DNA probe recog-
nizing the BamH1 Z fragment of the EBV genome [28].
Specific signals were quantified by densitometric analysis
(ImageJ freeshare software).
Western blot analysis
At the indicated times, samples (about 106 cells) were col-
lected, washed and lysed as described [38]. 30 μg of pro-
teins, as determined by a modified Lowry assay (RC DC
protein assay, BioRad), were resolved by SDS-PAGE on a
10% gel and transferred onto nitrocellulose membrane.
Primary antibodies used: LMP-1 (BD PharMingen),
EBNA2 (kind gift of Prof. M. Rowe), BZLF1 (Argene Bio-
soft), BFRF1 (kindly provided by Dr. A. Farina), β-actin
(Sigma), and Bcl-2 (Santa Cruz). Specific signals visual-
ized by ECL detection kit (Amersham Pharmacia Biotech)
were quantified by densitometric analysis (ImageJ free-
share software).
RT-PCR experiments
Isolation of total RNA, primers sequences and the size of
amplification products of LMP1, GAPDH and EBNA2,
were as previously reported [39]. Primers used for BZLF1
(DP 5'-TTCAAAGAGAGCCGACAGGA-3'; RP 5'-ATCG-
CAAGCTCCTTTGCCT-3') and for BFRF1 (DP 5'-CCTA-
GATCTAGTGAATCATG-3'; RP 5'-
TTCTGAAAAGTTATCCAAGT-3') amplified a product of
704 and 730 bp, respectively. PCR products were loaded
onto a 1.5% agarose gels with 0.5 μg/ml ethidium bro-
mide and visualized under UV light.
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